CCRM works with customers in a collaborative manner to enable them to accelerate the commercialization of new technologies. Our recent work with Nkarta Therapeutics is a great example.
Nkarta is a clinical-stage, cell therapy company focused on engineering natural killer (NK) cells for the treatment of cancer. As an emerging biotechnology company, Nkarta sought a
is. It extensive
CCRM’s regulatory experts helped Nkarta navigate a path to successful pre-Investigational New Drug (IND) meetings.
CCRM ensures customer success through a comprehensive approach based on the following four pillars:
- Extensive expertise
- Enabling technologies
- Collaborative processes
- Specialized infrastructure
Here we’ll focus on how CCRM’s dedication to collaborative processes helped Nkarta advance its therapy and prepare for a successful IND filing
Strong Communication Helped to Meet Tight Timelines
The foundation of any successful relationship is good communication. To ensure the project stayed on track, CCRM’s staff worked closely with Nkarta’s project leaders. Lead scientists from both organizations routinely exchanged ideas and strategies to keep the work moving forward. CCRM’s experts worked hard to understand Nkarta’s needs and provide specialized services and support.
By setting the project on the right path early, CCRM’s experienced professionals helped Nkarta identify the steps to success. Leveraging their decades of collective experience, the team at CCRM knew how to identify risks and provide mitigations. With that approach, they avoided costly dead-ends and helped Nkarta reduce the potential impacts to its timeline and budget.
Working with CCRM’s Regulatory Team Advanced Nkarta Towards Clinical Trials
With the same goals in mind, CCRM’s in-house regulatory experts leveraged their experience in working with Health Canada, the U.S. Food and Drug Administration, European Medicines Association and other global regulators. Further, Nkarta benefited from access to CCRM’s facilities that are designed to comply with North American Good Manufacturing Practices (GMP) and the European Union’s Advanced Therapy Medicinal Products Guidelines.
CCRM had the Right Tools for the Job
CCRM’s GMP-compliant facility, the Centre for Cell and Vector Production, houses CCRM’s Gammacell® irradiator (Best™ Theratronics) – a piece of equipment that is not commonly found in CDMOs. Nkarta utilized the irradiator, along with other cutting-edge tools, in processes that proved instrumental to the project.
Transparency Made Budget Discussions Easy to Approach
Dr. Nadir Mahmood, Chief Financial Officer and Chief Business Officer of Nkarta, played an active role in generating cost estimates and forecasts and discussed the project’s finances on frequent calls with CCRM representatives. Regular communication ensured financial estimates were tracking well, and that clinical supply would meet critical timelines.
Dr. Mahmood said CCRM and Nkarta’s cooperation felt “fluid,” and that CCRM’s willingness to connect and brainstorm was “critical” to the project’s budgetary success.
Why We Collaborate
By working openly together, organizations like CCRM and Nkarta can create synergies to advance the field.
Using the four pillars of its comprehensive approach as a foundation, CCRM helped Nkarta move towards realizing the potential of NK cells to treat cancer. We’re proud of this accomplishment and look forward to maintaining the momentum of our collaboration. `
To learn more about CCRM’s facilities, services and technologies, please visit our website.
To learn more about Nkarta and its research, visit Nkarta’s website.
To learn more about our work with Nkarta read our latest case study.
To learn about the commercialization of regenerative medicine, ask questions, or begin your journey with us, please email firstname.lastname@example.org